MAPT and Parkinson disease: iPSC-derived neurons from patients with Alzheimer’s disease (AD) or Parkinson’s disease (PD) or directly engineered cell lines ex-pressing amyloid beta (Aβ), hyperphosphorylated tau, or α-synuclein can be used to test compounds or biological agents that stimulate the reversal of aggregation or improve clearance.